PAR-25-338
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
Summary
PAR-25-338: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment
Research Focus
This program funds translational research that converts scientific discoveries and engineering developments into practical methods, tools, devices, assays, or systems for disease detection, diagnosis, treatment, and monitoring. The funder targets technologies addressing problems in basic research to understand disease mechanisms or applied research to assess risk, detect, prevent, diagnose, treat, and manage disease. Supported work spans pre-clinical, clinical, and non-clinical settings. Applicants may enhance, adapt, optimize, or validate existing or novel technologies—including machine learning, artificial intelligence, bioinformatics, and quantification methods—to improve affordability, reproducibility, quality assurance, analytical validation, or accessibility in low-resource and underserved populations. The program emphasizes transition from demonstration of feasibility to end-user-ready status, with innovation defined as likelihood to deliver new capability to end users rather than novelty alone.
At a Glance
- Who can apply: Academic-industrial partnerships with at least one academic and one industrial organization; academics with affiliated start-up companies allowed (with conflict-of-interest management).
- Funding & project length: R01 grant mechanism; specific amounts not stated.
- Award type: Research Project Grant (R01); clinical trials not allowed.
- Key dates: Open January 5, 2025; rolling deadlines through October 5, 2027; earliest start December 2025.
- Best fit for: Cancer, eye disease, dental/craniofacial research teams developing diagnostic assays, detection platforms, treatment devices, or clinical/research tools with industrial partners committed to manufacturability, regulatory compliance (GLP/GMP), and sustainable dissemination.
Note: Specific funding amounts and project duration not stated in this excerpt. Consult full FOA for budget details and review the January 2025 correction notice (NOT-CA-25-032).
Key Facts
Deadline
Fri, January 7, 2028
Posted
Tue, December 31, 2024
Award / Year (direct costs)
$500,000
Max Total
$2,500,000
Max Duration
5 years
Keywords
Research Areas
Gotchas (4)
Clinical trials are explicitly not allowed under this mechanism (R01 - Clinical Trial Not Allowed)
98%
Source Text
“Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)”
Mandatory partnership structure requirement: each application MUST include at least one academic AND one industrial organization. Solo applications or applications without both partner types will be i
98%
Source Text
“Each partnership should include at least one academic and one industrial organization.”
Funding explicitly does NOT support commercial production, only work up to pre-commercial production. Projects proposing manufacturing scale-up or commercial production activities will exceed scope.
95%
Source Text
“This NOFO will support work up to the point of pre-commercial production, but specifically does not support commercial production.”
Industrial partner involvement from the beginning of the project is expected/required for effective execution. Late-stage industrial involvement may not meet the partnership intent of this NOFO.
85%
Source Text
“Key parties are expected to participate from the beginning. Industrial involvement from the beginning is expected to facilitate more efficient transfer of intellectual property to the commercial setting.”